5 November 2026
17:00 CET | 16:00 GMT | 11:00 EST | 08:00 PST
Virtual screening and fragment-based screening methods, including Weak Affinity Chromatography (WAC), are efficient and informed methods for hit identification. However, advancing drug discovery programs beyond the initial screening hits remains a challenge. Employing workflows that fully leverage available data maximize the chances of success and can uncover new opportunities.
Our colleague Dr. Björn Borgström has spent a decade helping projects move through those decisions at RG Discovery. New to the wider Pelago Bioscience team? Yes. New to drug discovery? Very much no.
With RG Discovery now part of Pelago Bioscience, we’re pleased to introduce more of the people and expertise behind that work.
Join Björn for Smarter Drug Discovery: Turning Screening Hits into Opportunities, featuring practical case studies on:
• Creative approaches to getting early discovery projects moving
• Efficient hit identification for CDK9 and SMARCA4
• Using CETSA-based selectivity profiling to spot potential liabilities and new opportunities early
If you’re working with a lean team and need to make each project decision count, this session is for you.
